{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:15:47Z","timestamp":1790104547012,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T00:00:00Z","timestamp":1378166400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study of postmenopausal women with breast cancer on AIs who had completed a survey about their symptom experience on AIs with specific measurements of joint pain. The primary outcome was premature discontinuation of AIs, defined as stopping the medication prior to the end of prescribed therapy. Multivariate Cox regression modeling was used to identify predictors of premature discontinuation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 437 patients who met eligibility criteria, 47 (11%) prematurely discontinued AIs an average of 29 months after initiation of therapy. In multivariate analyses, patient-reported worst joint pain score of 4 or greater on the Brief Pain Inventory (BPI) (Hazard Ratio [HR] 2.09, 95% Confidence Interval [CI] 1.14-3.80, <jats:italic>P<\/jats:italic> = 0.016) and prior use of tamoxifen (HR 2.01, 95% CI 1.09-3.70, <jats:italic>P<\/jats:italic> = 0.026) were significant predictors of premature discontinuation of AIs. The most common reason for premature discontinuation was joint pain (57%) followed by other therapy-related side effects (30%). While providers documented joint pain in charts for 82% of patients with clinically important pain, no quantitative pain assessments were noted, and only 43% provided any plan for pain evaluation or management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Worst joint pain of 4 or greater on the BPI predicts premature discontinuation of AI therapy. Clinicians should monitor pain severity with quantitative assessments and provide timely management to promote optimal adherence to AIs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-401","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T08:14:52Z","timestamp":1378196092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors"],"prefix":"10.1186","volume":"13","author":[{"given":"Kannie","family":"Chim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon X","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie T","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing S","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"DeMichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun J","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"issue":"11","key":"4046_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. NEJM. 2004, 350 (11): 1081-1092. 10.1056\/NEJMoa040331.","journal-title":"NEJM"},{"issue":"22","key":"4046_CR2","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","volume":"23","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005, 23 (22): 5138-10.1200\/JCO.2005.04.120.","journal-title":"J Clin Oncol"},{"issue":"9453","key":"4046_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365 (9453): 60-62.","journal-title":"Lancet"},{"issue":"26","key":"4046_CR4","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Th\u00fcrlimann","year":"2005","unstructured":"Th\u00fcrlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM. 2005, 353 (26): 2747-","journal-title":"NEJM"},{"issue":"23","key":"4046_CR5","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J: American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010, 28 (23): 3784-3796. 10.1200\/JCO.2009.26.3756.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4046_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011, 126 (2): 529-537. 10.1007\/s10549-010-1132-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"4046_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","volume":"26","author":"AH Partridge","year":"2008","unstructured":"Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008, 26 (4): 556-562. 10.1200\/JCO.2007.11.5451.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4046_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-011-1351-3","volume":"126","author":"SF Dent","year":"2011","unstructured":"Dent SF, Gaspo R, Kissner M, Pritchard KI: Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011, 126 (2): 295-310. 10.1007\/s10549-011-1351-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"4046_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012, 30 (9): 936-942. 10.1200\/JCO.2011.38.0261.","journal-title":"J Clin Oncol"},{"issue":"21","key":"4046_CR10","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1200\/JCO.2008.19.2419","volume":"27","author":"G Kimmick","year":"2009","unstructured":"Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R: Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009, 27 (21): 3445-3451. 10.1200\/JCO.2008.19.2419.","journal-title":"J Clin Oncol"},{"issue":"27","key":"4046_CR11","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010, 28 (27): 4120-4128. 10.1200\/JCO.2009.25.9655.","journal-title":"J Clin Oncol"},{"issue":"18","key":"4046_CR12","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","volume":"29","author":"AI Neugut","year":"2011","unstructured":"Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, Grann VR, Hershman DL: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011, 29 (18): 2534-2542. 10.1200\/JCO.2010.33.3179.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4046_CR13","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007, 25 (25): 3877-3883. 10.1200\/JCO.2007.10.7573.","journal-title":"J Clin Oncol"},{"issue":"16","key":"4046_CR14","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.24419","volume":"115","author":"JJ Mao","year":"2009","unstructured":"Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A: Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009, 115 (16): 3631-3639. 10.1002\/cncr.24419.","journal-title":"Cancer"},{"issue":"3","key":"4046_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pds.3365","volume":"22","author":"JJ Mao","year":"2013","unstructured":"Mao JJ, Chung A, Benton A, Hill S, Ungar L, Leonard CE, Hennessy S, Holmes JH: Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013, 22 (3): 256-262. 10.1002\/pds.3365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4046_CR16","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/bcr2813","volume":"13","author":"JJ Mao","year":"2011","unstructured":"Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, DeMichele A: Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res. 2011, 13: R8-10.1186\/bcr2813.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"4046_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-011-1801-y","volume":"131","author":"U Guth","year":"2011","unstructured":"Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM: Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat. 2011, 131 (2): 491-499.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"4046_CR18","first-page":"129","volume":"23","author":"C Cleeland","year":"1994","unstructured":"Cleeland C, Ryan K: Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994, 23 (2): 129-138.","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"4046_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0885-3924(91)90518-9","volume":"6","author":"SA Grossman","year":"1991","unstructured":"Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S: Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manag. 1991, 6 (2): 53-57. 10.1016\/0885-3924(91)90518-9.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"4046_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2001.19.2.501","volume":"19","author":"DJ Rhodes","year":"2001","unstructured":"Rhodes DJ, Koshy RC, Waterfield WC, Wu AW, Grossman SA: Feasibility of quantitative pain assessment in outpatient oncology practice. J Clin Oncol. 2001, 19 (2): 501-508.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4046_CR21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.6004\/jnccn.2010.0076","volume":"8","author":"R Swarm","year":"2010","unstructured":"Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Eilers JG, Ferrell B: Adult cancer pain. J Natl Compr Canc Netw. 2010, 8 (9): 1046-1086.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"4046_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.2010.30.3909","volume":"29","author":"DL Berry","year":"2011","unstructured":"Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R: Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol. 2011, 29 (8): 1029-1035. 10.1200\/JCO.2010.30.3909.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4046_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1534735409332903","volume":"8","author":"JJ Mao","year":"2009","unstructured":"Mao JJ, Bruner DW, Stricker C, Farrar JT, Xie SX, Bowman MA, Pucci D, Han X, DeMichele A: Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther. 2009, 8 (2): 123-129. 10.1177\/1534735409332903.","journal-title":"Integr Cancer Ther"},{"issue":"7","key":"4046_CR24","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2009.23.4708","volume":"28","author":"KD Crew","year":"2010","unstructured":"Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Tsai WY, Hershman DL: Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010, 28 (7): 1154-1160. 10.1200\/JCO.2009.23.4708.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4046_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10549-009-0495-x","volume":"119","author":"QJ Khan","year":"2010","unstructured":"Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, ODea AP, Klemp JR, Fabian CJ: Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010, 119 (1): 111-118. 10.1007\/s10549-009-0495-x.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-401\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:21:46Z","timestamp":1630545706000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4046"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-401","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,3]]},"assertion":[{"value":"13 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"401"}}